Example: Heart Attack

Search clinical trials for: Arsenic trioxide

Total 137 results

    • NCT04695223
      Recruiting
      Arsenic Trioxide for Structural p53 Mutations
      Conditions: Arsenic Trioxide; p53 Mutations; Refractory Cancer; Intractable Cancer
    • NCT03980665
      Recruiting
      The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
      Conditions: HIV/AIDS
    • NCT03503864
      Recruiting
      Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma
      Conditions: Neuroblastoma
    • NCT04689815
      Recruiting
      Oral Arsenic Trioxide for NPM1-mutated AML
      Conditions: NPMc+ AML
    • NCT04687176
      Recruiting
      Frontline Oral Arsenic Trioxide for APL
      Conditions: Acute Promyelocytic Leukemia
    • NCT04489706
      Recruiting
      Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
      Conditions: Ovarian Cancer; Endometrial Cancer
    • NCT03624270
      Recruiting
      Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
      Conditions: Acute Promyelocytic Leukemia
    • NCT02066870
      Unknown status
      Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
      Conditions: Non-small Cell Lung Cancer
    • NCT01470248
      Completed
      Study of Arsenic Trioxide in Small Cell Lung Cancer
      Conditions: Lung Cancer; Cancer of Lung; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Small Cell
    • NCT02966301
      Completed
      Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
      Conditions: Chronic Graft-Versus-Host Disease; Immune System Diseases
    • NCT01738360
      Terminated
      Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
      Conditions: Systemic Lupus
    • NCT01184053
      Terminated
      Trisenox® in Women With Metastatic Endometrial Cancer
      Conditions: Endometrial Carcinoma
    • NCT01791894
      Completed
      Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
      Conditions: Basal Cell Carcinoma of the Skin; Recurrent Skin Cancer
    • NCT04518501
      Active, not recruiting
      Olaparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
      Conditions: Efficacy and Safety
    • NCT03751917
      Recruiting
      Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
      Conditions: Acute Promyelocytic Leukemia
    • NCT00006092
      Terminated
      Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
      Conditions: Leukemia
    • NCT01835288
      Withdrawn
      Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
      Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
    • NCT02956772
      Unknown status
      Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
      Conditions: Primary Hepatocellular Carcinoma
    • NCT02018757
      Unknown status
      Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
      Conditions: Carcinoma, Hepatocellular
    • NCT00582400
      Terminated
      A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
      Conditions: Carcinoma, Hepatocellular
    • NCT01861912
      Unknown status
      Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
      Conditions: Carcinoma, Hepatocellular
    • NCT00009867
      Completed
      Arsenic Trioxide in Treating Patients With Urothelial Cancer
      Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Transitional Cell Carcinoma of the Bladder; Ureter Cancer
    • NCT02757040
      Unknown status
      Combination of Ibrutinib and As2O3 in the Treatment of CLL
      Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    • NCT00061958
      Terminated
      Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
      Conditions: Adenocarcinoma of the Esophagus; Stage III Esophageal Cancer; Stage IV Esophageal Cancer
    • NCT00513305
      Terminated
      Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
      Conditions: Acute Myeloid Leukemia
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations